Compositions comprising hydrolyzed colarate salts and their use in skin antiaging and protection

By using oligopolysodium colalate with a molecular weight in the range of 1-10kDa, the shortcomings of existing skin care products and pharmaceutical products in improving skin collagen and cell viability are solved, and significant skin anti-aging and protective effects are achieved.

CN119095580APending Publication Date: 2024-12-06SHENZHEN PAM2L BIOTECHNOLOGIES CO LTD

Patent Information

Application Number
CN202480002002.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-09
Filing Date
2024-06-27
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing skin care products and pharmaceutical products are difficult to effectively improve the collagen content and cell vitality of the skin, and have limited effects in skin protection and anti-aging.

Method used

Using colalate with a molecular weight in the range of 1-10kDa, especially oligosol sodium colalate, as active ingredient, to obtain colalate with different molecular weights through various preparation methods, for skin anti-aging and protection, combined with Cosmetics or pharmaceutical additives are formulated into cosmetics or pharmaceutical compositions.

Benefits of technology

Significantly improve the collagen content in the skin, enhance the protective function of skin cells, improve the skin condition and appearance, promote collagen synthesis, and have good anti-aging and skin protection effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HSB0000209491410000011
    Figure HSB0000209491410000011
  • Figure HSB0000209491410000012
    Figure HSB0000209491410000012
  • Figure HSB0000209491410000021
    Figure HSB0000209491410000021
Patent Text Reader

Abstract

The invention relates to the field of skin care products and medicines, and particularly provides a composition containing corallite and application of the composition in skin aging resistance and skin protection. The corac acid salt disclosed by the invention has good skin anti-aging and skin protection effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of skin care products and medicines, and in particular relates to a composition containing hydrolyzed colanate and application thereof in skin anti-aging and skin protection. Background Art

[0002] Colanic acid (CA) is a bacterial extracellular polysaccharide produced by most strains of Escherichia coli and other species of the Enterobacteriaceae family. It is a polysaccharide synthesized by bacteria in order to adapt to environmental changes and improve their own survival rate during life activities. CA has a large molecular weight and is loosely wrapped on the surface of the bacteria, making the bacteria appear in a mucus state, preventing cell dehydration, protecting cells and resisting harmful substances. Under environmental conditions that are not conducive to growth, such as dryness, low pressure and low pH, mucoid strains have stronger survival than wild strains. In 2017, Han et al. reported that feeding purified CA or feeding Escherichia coli that can secrete CA can significantly extend the lifespan of Caenorhabditis elegans. In addition, as a unique active biopolymer, CA has special biological properties and physiological parameters and has broad application prospects. Summary of the invention

[0003] In one aspect, the present disclosure provides use of colanic acid or a physiologically acceptable salt thereof, or a composition comprising colanic acid or a physiologically acceptable salt thereof, in skin anti-aging and / or skin protection, wherein the molecular weight of the colanic acid or a physiologically acceptable salt thereof is in the range of 1-10 kDa.

[0004] In some embodiments, the skin anti-aging comprises increasing the collagen content in the skin, preferably the content of type I and type III collagen.

[0005] In some embodiments, the skin protection comprises enhancing the protective function of skin cells such as increasing the viability of skin cells.

[0006] In some embodiments, said skin anti-aging and said skin protection comprises improving skin condition or appearance.

[0007] In some embodiments, the content of colanic acid or a physiologically acceptable salt thereof is 0.01-10% (w / v), 0.1-5% (w / v), or 0.5-3% (w / v).

[0008] In some embodiments, the physiologically acceptable salt of colanic acid is sodium colanate.

[0009] In some embodiments, the colanic acid or a physiologically acceptable salt thereof, or a composition comprising colanic acid or a physiologically acceptable salt thereof, is formulated for topical, oral, intramuscular, subcutaneous, or intravenous administration.

[0010] In some embodiments, the composition comprising colanic acid or a physiologically acceptable salt thereof further comprises a cosmetically or pharmaceutically acceptable additive.

[0011] In another aspect, the present disclosure provides use of colanic acid or a physiologically acceptable salt thereof, or a composition comprising colanic acid or a physiologically acceptable salt thereof, as described above, in the preparation of a medicament or cosmetic for skin anti-aging and / or skin protection.

[0012] In another aspect, the present disclosure provides a composition comprising colanic acid or a physiologically acceptable salt thereof as an effective ingredient, wherein the molecular weight of the colanic acid or the physiologically acceptable salt thereof is in the range of 1-10 kDa.

[0013] In some embodiments, the molecular weight of the colanic acid or a physiologically acceptable salt thereof is in the range of 1-3 kDa or 3-10 kDa.

[0014] In some embodiments, the content of colanic acid or a physiologically acceptable salt thereof in the composition is 0.01-10% (w / v), 0.1-5% (w / v), or 0.5-3% (w / v).

[0015] In some embodiments, the composition comprises only colanic acid or a physiologically acceptable salt thereof as an active ingredient.

[0016] In some embodiments, the composition is formulated for topical, oral, intramuscular, subcutaneous, or intravenous administration.

[0017] In some embodiments, the composition is formulated for topical administration.

[0018] In some embodiments, the composition further contains cosmetically or pharmaceutically acceptable additives.

[0019] In some embodiments, the physiologically acceptable salt of colanic acid is sodium colanate. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The invention can be more fully understood with reference to the following drawings.

[0021] Figure 1 The results of transcriptome analysis of fibroblasts by large and small molecular weight sodium colanate are shown.

[0022] Figure 2 The multi-dimensional anti-aging efficacy mechanism of colanic acid is shown.

[0023] Figure 3 The results of transcriptome analysis of human fibroblasts by oligocorticosteroids are shown.

[0024] Figure 4 The results of transcriptome analysis of human fibroblasts by oligocorticosteroids (A) and cell viability test results after UVA irradiation (B) are shown.

[0025] Figure 5 The results show the inhibitory effect of sodium oligocorticate on macrophage TNF-α and IL-6.

[0026] Figure 6 The results of transcriptional regulation of oligocorticosteroid sodium on genes related to mitochondrial homeostasis repair in human fibroblasts are shown.

[0027] Figure 7 The results show the transcriptional analysis of oligocorticosteroid sodium on SOD2 and GPX1 / 8 in HDF cells (A) and the scavenging effect on reactive oxygen species (B).

[0028] Figure 8 The data show that sodium oligocorticate promotes the synthesis of type I collagen in HDF cells and upregulates the transcription of different types of collagen in HDF cells.

[0029] Fig. 9 The phototoxicity test results of oligomeric sodium colanate are shown.

[0030] Fig.10 The results of the activity test of oligomeric colanic acid in promoting the synthesis of type I collagen and type III collagen by HDF cells under light conditions are shown.

[0031] Fig.11 The results show the inhibitory effect of sodium oligocorticate on MMP9 in the UV-irradiated skin model.

[0032] Fig.12 The anti-inflammatory effect of sodium oligocorate on human keratinocytes was shown.

[0033] Fig.13 The results of the skin permeability test of oligomeric sodium colanate are shown.

[0034] Fig.14 The results of the intracellular localization test of oligomeric sodium colanate are shown.

[0035] Fig.15 The results of the cytotoxicity test of sodium oligocorticate are shown.

[0036] Fig.16 The results show that oligomeric sodium colanate has an effect on increasing the density of the human dermis.

[0037] Fig.17 The results show that sodium oligocorticate has an effect on increasing the expression of collagen in the human dermis.

[0038] Fig.18The results show that oligomeric sodium colanate has an effect on increasing the expression of elastin in the human dermis.

[0039] Fig.19 The results show that oligomeric sodium colanate has an effect on improving the elasticity and refinement of human skin.

[0040] Fig. 20 The results show the effect of oligomeric sodium colanate on the normalized area of ​​DEJ in human skin.

[0041] Fig.21 The results show that oligomeric sodium colanate has an effect on increasing the thickness of the epidermis of human skin.

[0042] Fig. 22 The results show that sodium oligocorticate has an improving effect on redness of human skin.

[0043] Fig.23 The results show the effect of oligomeric sodium colanate on increasing the content of 3D skin filaggrin (FLG).

[0044] Fig.24 The results show the effect of oligomeric sodium colanate on increasing the content of aquaporin 3 (AQP3) in 3D skin.

[0045] Fig.25 The results show the effect of oligomeric sodium colanate on locking moisture in human skin.

[0046] Fig.26 The effect of oligocorticate sodium on stimulating the expression of type I collagen in human fibroblasts is shown.

[0047] Fig. 27 The skin protective effect of oligomeric sodium colanate is shown.

[0048] In the figure, * indicates P < 0.05 relative to the negative control, ** indicates P < 0.01 relative to the negative control, *** indicates P < 0.001 relative to the negative control, ## indicates P < 0.01 relative to the blank control, and ### indicates P < 0.001 relative to the blank control. DETAILED DESCRIPTION OF THE INVENTION

[0050] Various features and aspects of the invention are discussed in greater detail below.

[0051] Figure 1The transcriptome analysis results of small molecule colanate (molecular weight of 1-3kDa, hereinafter also referred to as hydrolyzed or oligomeric colanate, referred to as oligomeric CA or Oli-CA) and large molecule colanate (molecular weight of 10-6000kDa) are shown. Specifically, they were added to human fibroblasts (HDF) cultured for 24 hours, then irradiated with ultraviolet light, and cultured for another 24 hours, and then the cells were taken out for transcriptome analysis. According to the test results, statistical analysis was performed on the upregulation or downregulation of different genes, and the results showed that colanate had an effect on 2,500 genes in the cells. The control group, cucurbitacin, only had an effect on 426 genes. These results show that colanate with different molecular weights has a very large effect on the transcriptome of fibroblasts.

[0052] Based on the results of transcriptome analysis and combined with the KEGG longevity-related pathways (https: / / www.kegg.jp / pathway / map04211), different anti-aging pathways of colanate were sorted out and are shown in Figure 2 . Figure 2 The middle gray part indicates that the transcriptome mRNA is inhibited, the green part indicates that the transcriptome mRNA is upregulated, the pointed arrow indicates promoted expression, and the blunt arrow indicates inhibited expression. Figure 2 It shows that in pathway 1, colanate can promote the transcriptome of NAMPT, a key enzyme for synthesizing NAD+ in cells. At the same time, colanate can also upregulate genes such as AMPK and sirt1, and further inhibit BAX and NF-κ, thereby inhibiting cell apoptosis and cellular inflammation. It can also upregulate PGC-1α and promote mitochondrial activity.

[0053] In pathway 2, colanate can inhibit Rheb and mTOR genes, thereby upregulating the transcription of ATG13 and RB1CC1 genes and promoting cellular autophagy.

[0054] In pathway 3, colanate can promote mitochondrial autophagy by upregulating the expression of genes such as AMBRA1, USP8, and ATF4, promote mitochondrial fission by upregulating HIF1 and promoting the transcription of BNIP3 and BCL2L13, and promote the mitochondrial unfolded protein response by promoting the transcription of ATF4 / ATF5 and CHOP. The above three aspects synergistically promote the remodeling of mitochondrial homeostasis.

[0055] In pathway 4, colanate increases the activity of cells to scavenge ROS by upregulating the transcription of SOD2, GPX1, and GPX8. In addition to scavenging reactive oxygen species, the upregulated expression of GPX8 can also regulate the transfer of calcium ions from the endoplasmic reticulum to mitochondria, alleviating mitochondrial damage caused by the regulation of intracellular calcium ion loss.

[0056] In pathway 5, colanate promotes the synthesis of extracellular matrix by upregulating the transcriptome expressing collagen and various extracellular matrices, thereby enhancing intercellular communication and providing better support and protection for cell morphology.

[0057] In the present disclosure, colanic acid (CA) or colanic acid salts can be prepared by any method as long as the desired molecular weight can be obtained. Specifically, the molecular weight of colanic acid or its physiologically acceptable salt can be 1 kDa, 2 kDa, 3 kDa, 4 kDa, 5 kDa, 6 kDa, 7 kDa, 8 kDa, 9 kDa or 10 kDa, or any range of the above molecular weights. Among them, the molecular weight is 1-10 kDa, 1-8 kDa, 1-6 kDa, 1-5 kDa, 1-4 kDa, 1-3 kDa, 1-2 kDa, 2-10 kDa, 2-8 kDa, 2-6 kDa, 2-4 kDa, 2-3 kDa, 3-6 kDa, 4-10 kDa, 4-8 kDa, 4-6 kDa, 5-10 kDa, 5-8 kDa, 6-10 kDa, or 6-8 kDa, which can further improve the effect of colanic acid or its physiologically acceptable salt.

[0058] The inventors of the present invention unexpectedly discovered that by selecting colanic acid or a physiologically acceptable salt thereof having the above-specified molecular weight, its efficacy in skin anti-aging and skin protection (e.g., improving skin condition or appearance, such as skin anti-aging, especially increasing the collagen content in the skin) can be further improved.

[0059] For example, colanic acid or its physiologically acceptable salt can be prepared by the method of CN115287314B. In addition, colanic acid or its physiologically acceptable salt can also be purified by the method of CN114957509A. It should be understood by those skilled in the art that colanic acid or colanate salts of different molecular weight ranges can be obtained by conventional preparation methods.

[0060] The term "physiologically acceptable salt" may be any salt derived from colanic acid. In the present invention, these salts are not limited to specific types as long as they can be used in cosmetic and pharmaceutical compositions. Specific examples thereof include alkali metal salts such as sodium, potassium and lithium salts; alkaline earth metal salts such as calcium, magnesium, barium and zinc salts; alkylamine salts such as ammonia, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, propylamine, butylamine, tetrabutylamine, pentylamine and hexylamine; alkanolamine salts such as ethanolamine, diethanolamine, triethanolamine, propanolamine, dipropanolamine, isopropanolamine and diisopropanolamine; salts of other organic amines such as piperazine and piperidine; salts of basic amino acids such as lysine, arginine, histidine and tryptophan, etc. In the present disclosure, the physiologically acceptable salt of colanic acid may be sodium colanate.

[0061] The composition of the present invention can be used as a pharmaceutical composition or a cosmetic composition. The dosage form of the composition can be specifically selected as needed. For example, the dosage form of the cosmetic composition can include emulsions, creams, lotions, essences, facial masks, gels, powders, lipsticks, cosmetic bases, foundations, lotions, ointments, patches, beauty serums, decontamination foams, decontamination creams, clean water, soaps or sprays. The dosage form of the pharmaceutical composition can include lozenges, capsules, emulsions, dispersants, suspensions, solutions, syrups, granules, transdermal patches, gels, powders, creams, ointments, suppositories or sprays. The pharmaceutical composition can be formulated for topical, oral, intramuscular, subcutaneous or intravenous administration.

[0062] In the composition of the present invention, the content of colanic acid or its physiologically acceptable salt can be selected as needed, for example, it can be 0.01-10% (w / v), 0.1-5% (w / v), or 0.5-3% (w / v).

[0063] In addition, as required, the pharmaceutical composition or cosmetic composition of the present invention may contain additives commonly added to pharmaceutical compositions or cosmetic compositions in addition to the necessary active ingredients. Examples of the additives include oily ingredients, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, antibacterial agents, antioxidants, plant extracts, pH regulators, alcohols, colorants, fragrances, blood circulation promoters, cooling agents, antiperspirants, water, and the like.

[0064] In some embodiments, the composition of the present invention comprises only colanic acid or its physiologically acceptable salt as an active ingredient. In some embodiments, the composition of the present invention further comprises other active ingredients, such as bosaiin, retinol and its derivatives (such as retinol propionate), retinal, retinoic acid, hyaluronic acid, ergothioneine, ectoine, etc.

[0065] In the present disclosure, the molecular weight of colanic acid or its physiologically acceptable salt is determined by liquid chromatography. The specific method is as follows: accurately weigh the sample and the standard, prepare the sample into a 2 mg / mL solution, and filter it into a 1.8 mL injection vial with a 0.22 μm syringe filter after fully dissolving. Chromatographic column: PolySep-GFC-P (35*7.8 mm); PolySep-GFC-P 4000 (300*7.8 mm); PolySep-GFC-P 6000 (300*7.8 mm); mobile phase: 0.02M NaCl solution; flow rate: 0.6 mL / min, column temperature: 40°C; injection volume: 20 μL; detector: differential detector 1260-RID.

[0066] Preparation method

[0067] In the following examples, oligomeric sodium colanate (1-10 kDa) was prepared by the following method.

[0068] The obtained colanic acid product is mixed with colanic acid degrading enzyme (produced by Baiyin Biological, see SEQ ID No. 2 in CN116334039B) at different concentrations (2000U / L, 3000U / L, 5000U / L) at 37°C for 10-12h, the sample is collected and heated to inactivate the enzyme, and then separated and purified using a DEAE ion column to remove a small amount of molecular weight inhomogeneous parts and impurities to obtain sodium colanate products with different molecular weights. The final product can be obtained by freeze drying or spray drying. The molecular weight of the obtained sodium colanate is 1-10 kDa, 1-8 kDa, 1-6 kDa, 1-5 kDa, 1-4 kDa, 1-3 kDa, 1-2 kDa, 2-10 kDa, 2-8 kDa, 2-6 kDa, 2-4 kDa, 2-3 kDa, 3-6 kDa, 4-10 kDa, 4-8 kDa, 4-6 kDa, 5-10 kDa, 5-8 kDa, 6-10 kDa, or 6-8 kDa.

[0069] Among them, the colanic acid product macromolecular sodium colanate (3000-6000 kDa) is prepared by the following method.

[0070] 1. Solid-liquid separation

[0071] 1) Dilution: Pump the fermentation broth into a storage tank, dilute it 3-20 times with 10-60% calcium chloride solution (the amount of calcium chloride is 2% (w / v) of the fermentation broth) and purified water, and stir for 2-3 hours until it is fully dissolved.

[0072] 2) Flocculation: Sodium carbonate solid was added to adjust the pH to 9.0-12.0, and flocculation was performed for 1-2 hours before premixing with diatomaceous earth (the amount of diatomaceous earth was 1% (w / v) of the fermentation liquid).

[0073] 3) Plate and frame filtration: follow the plate and frame filter press operation SOP, install the filter cloth, and press the filter plate. Use 0.5M sodium hydroxide solution to circulate and flush the plate and frame filter press system for 15 minutes, and then rinse with purified water until the pH test paper is neutral. Start the feed pump to pump in the diatomaceous earth suspension (pre-coating amount is 0.5kg / m 2 ), pre-coat diatomaceous earth on the plate and frame. After the pre-coating is completed, connect the liquid inlet to the liquid storage tank and pump in the flocculation liquid for circulating filtration of the plate and frame filter, and control the working pressure to <0.2MPa. Put the outlet of the liquid collection pipe into the feed tank for circulating filtration. After the liquid at the outlet is clarified (turbidity ≤50NTU), start collecting the filtrate. After the end, wash with 1-2 times the dead volume of purified water.

[0074] 2. Activated carbon adsorption

[0075] 1) Adsorption: Add injection-grade activated carbon at 0.5% of the fermentation liquid weight, adjust the pH to 4-6 with 0.1M HCl, and stir for 1-2 hours. After the adsorption is completed, pre-mix diatomaceous earth (the amount of diatomaceous earth is 0.1-5% (w / v) of the fermentation liquid).

[0076] 2) Plate and frame filtration: According to the plate and frame filter press operation SOP, install the filter cloth and press the filter plate. Start the feed pump to pump in the diatomaceous earth suspension (pre-coating amount is 0.5kg / m 2 ), pre-coat diatomaceous earth on the plate frame. After the pre-coating is completed, connect the liquid inlet to the liquid storage tank and pump in the flocculation liquid for circulating filtration of the plate and frame filter, and control the working pressure to <0.2MPa. Connect the liquid inlet to the filtrate collection tank for circulating filtration, and start collecting the filtrate after the liquid at the outlet is clarified (turbidity ≤30NTU).

[0077] After completion, top wash with 1-2 times the dead volume of purified water.

[0078] 3. Fine filtration

[0079] The pH of the filtrate is adjusted to 7.0±0.2 with solid sodium carbonate, and then the filtrate is finely filtered with a 20-inch ultra-high precision PP filter element in series with a PES filter element. Slowly increase the feed flow rate to make the filtration pressure ≤0.1MPa. If the pressure is too high, backwash and drain the feed liquid, replace the filter and filter again. When there is continuous liquid flowing out of the exhaust port, close the exhaust valve to collect the filtrate.

[0080] 4. Ceramic membrane concentration

[0081] 1) Cleaning: Connect the ceramic membrane ultrafiltration system, and rinse the ceramic membrane system with 2% citric acid, purified water, and 0.5M NaOH solution in a cycle for 15-30 minutes, and then rinse with purified water until the pH test paper at the permeate end is neutral.

[0082] 2) Concentration: Use a pump to pump the finely filtered liquid into the ceramic membrane circulation storage tank, connect the reflux outlet to the circulation storage tank, and then open the tank bottom valve. Fully open the reflux valve and the permeate valve at one end. Start the system, control the frequency to 10-80Hz, and control the feed flow rate at 100-1500L / h. By setting the alarm pressure to 0.1MPa, control the inlet pressure to <0.1MPa (if overpressure, reduce the feed flow rate). Stop concentrating when the circulation concentration reaches 1 / 2 of the fermentation liquid volume or the inlet pressure is ≥0.1MPa. Close the permeate valve, and circulate and flush the ceramic membrane system with purified water 1-5 times the dead volume of the system for 5-30 minutes, empty and collect the reflux end liquid again, and repeat the above flushing and collection operations twice. Combine the collected concentrate and flushing liquid.

[0083] 5. Alcohol precipitation

[0084] 1) Sodium salt treatment: Add 10-40% sodium chloride solution (final concentration of sodium chloride 1-5%) to the concentrate and rinse solution, and stir evenly. Then use a 20-inch ultra-high precision PP filter element in series with a PES filter element for fine filtration. Slowly increase the feed flow rate to make the filtration pressure ≤ 0.1MPa. If the pressure is too high, backwash and drain the feed liquid, replace the filter and filter again, and collect the filtrate.

[0085] 2) Ethanol precipitation: Use citric acid, purified water, and NaOH solution to clean the alcohol precipitation tank in a cycle for 15-30 minutes, then rinse with purified water until the pH test paper is neutral. Pump the filtrate from the previous step into the alcohol precipitation tank, start stirring, and slowly add 95% ethanol twice the volume of the feed liquid. After stirring until a large amount of white flocculent precipitate is produced, stop stirring. Let it settle for 2-4 hours, remove the supernatant, and collect the precipitate.

[0086] 6. Washing and dehydration

[0087] 1) Washing: Add 1-10 times of 70% ethanol (containing 1% sodium chloride) to the CA sugar precipitate, stir and wash for 20 minutes, then let it stand for 1-8 hours, remove the supernatant, and collect the precipitate. Then repeat the washing twice and collect the precipitate.

[0088] 2) Dehydration: Add 1-10 times the volume of 95% ethanol to the precipitate, stir and dehydrate for 2 hours, let it stand for 1-2 hours, and then remove the supernatant. Repeat the above dehydration operation once more and collect the precipitate. After vacuum filtration of the precipitate to reduce the residual liquid, add 1-10 times the volume of 95% ethanol again for dehydration. Collect the precipitate, filter it again to remove the liquid, and weigh the wet weight of the sample.

[0089] 7. Drying

[0090] Place the wet weight sample in a vacuum drying oven (sample thickness not exceeding 2 cm), set the drying temperature to 45°C, and the drying time to 15 hours. Turn the sample over every 4 hours.

[0091] 8. Crushing and sieving

[0092] After the secondary drying, the sample was crushed again with a pulverizer, passed through a 100-mesh sieve, and packaged into aluminum foil bags.

[0093] Experimental methods

[0094] (1) Cytotoxicity

[0095] Cell culture: HDF cells were cultured in DMEM complete medium (DMEM+10% FBS+1% P / S) and placed in a 37°C, 5% CO2 incubator.

[0096] Sample processing: CA powder was dissolved in the culture medium and after complete dissolution, the solution was sterilized by filtering with a 0.2 μm sterile filter membrane.

[0097] Experimental treatment: HDF cells were inoculated into 96-well plates, and sample groups, blank controls (BC), and positive controls (PC) were set up. At least 3 replicates were performed for each sample for each test indicator. After 24 hours of culture, the culture medium was discarded, and the corresponding CA solution was added to the sample group, 10% DMSO solution was added to the positive control group, and complete culture medium was added to the blank control group. Culture was continued for 24 hours.

[0098] Cell viability detection: discard the supernatant, add complete medium containing 10% AlamarBlue, place in an incubator and incubate for 4 hours, then use a microplate reader to detect the absorbance at ex / em=560 / 590nm.

[0099] (2) Photodamage

[0100] Cell culture: HDF cells were cultured in DMEM complete medium (DMEM+10% FBS+1% P / S) and placed in a 37°C, 5% CO2 incubator.

[0101] Sample processing: CA powder was dissolved in the culture medium and after complete dissolution, the solution was sterilized by filtering with a 0.2 μm sterile filter membrane.

[0102] Experimental treatment: HDF cells were inoculated into 96-well plates, and sample groups, blank control groups (BC), positive control groups (PC), and negative control groups (NC) were set up. At least 3 replicate wells were set up for each sample for each test indicator. After 24 hours of culture, the culture medium was discarded, the corresponding CA solution was added to the sample group, the VC solution (dissolved in the culture medium) was added to the positive control group, and complete culture medium was added to the negative control group and the blank control group. Place in an incubator and incubate for 2 hours. The sample group, positive control group, and negative control group were irradiated under a UVA lamp with an irradiation dose of 5J / cm 2 After irradiation, the cells were cultured for 24 h.

[0103] Cell viability detection: discard the supernatant, add complete medium containing 10% AlamarBlue, put into the incubator for incubation for 4 hours, and then use a microplate reader to detect the absorbance value at ex / em=560 / 590.

[0104] Type I collagen detection: The supernatant of each well was collected and the test was performed according to the operating instructions of the ELISA collagen detection kit (Huamei Biotechnology, CSB-E08082h).

[0105] (3) Anti-wrinkle (promoting collagen)

[0106] Cell culture: HDF cells were cultured in DMEM complete medium (DMEM+10% FBS+1% P / S) and placed in a 37°C, 5% CO2 incubator.

[0107] Sample processing: CA powder was dissolved in the culture medium and after complete dissolution, the solution was sterilized by filtering with a 0.2 μm sterile filter membrane.

[0108] Experimental treatment: HDF cells were inoculated into 96-well plates, and sample groups, blank controls (BC), and positive controls (PC) were set up. At least 3 replicates were performed for each sample for each test indicator. After 24 hours of culture, the culture medium was discarded, the corresponding CA solution was added to the sample group, the TGF-β solution was added to the positive control group, and complete culture medium was added to the negative control group and the blank group. Culture was continued for 24 hours.

[0109] Type I and III collagen detection: Collect the supernatant from each well and perform the test according to the operating instructions of the ELISA collagen detection kit (Huamei Biotechnology, CSB-E04799h).

[0110] (4) Inflammation (macrophages)

[0111] Cell culture: RAW264.7 cells were cultured in DMEM complete medium (DMEM+10% FBS+1% P / S) and cultured in a 37°C, 5% CO2 incubator.

[0112] Sample processing: CA powder was dissolved in the culture medium and after complete dissolution, the solution was sterilized by filtering with a 0.2 μm sterile filter membrane.

[0113] Experimental treatment: RAW264.7 cells were inoculated into 96-well plates, and sample groups, blank controls, positive controls, and negative controls were set up. At least 3 replicates were performed for each sample for each test indicator. After 24 hours of culture, the culture medium was discarded, the corresponding CA solution was added to the sample group, the complete culture medium containing 100g / mL dexamethasone was added to the positive control group, and the complete culture medium was added to the negative control group and the blank group. After incubation in the incubator for 2 hours, 1μg / mL LPS (lipopolysaccharide) was added to the sample group, positive control group, and negative control. Continue to culture for 24 hours.

[0114] Inflammatory factor detection: Collect the supernatant of each well and perform the test according to the operating instructions of the ELISA kit (Huamei Biotechnology, CSB-E04740h, CSB-E08053h, CSB-E04638h).

[0115] Reactive oxygen species (ROS) detection: After collecting the supernatant, the cells in each well were washed twice with PBS, and the test was performed according to the operating instructions of the DCFH-DA kit.

[0116] (5) Inflammation (keratinocytes)

[0117] Cell culture: Keratinocytes HaCaT were cultured in DMEM complete medium (DMEM+10% FBS+1% P / S) and cultured in a 37°C, 5% CO2 incubator.

[0118] Sample processing: CA powder was dissolved in the culture medium and after complete dissolution, the solution was sterilized by filtering with a 0.2 μm sterile filter membrane.

[0119] Experimental treatment: The cells were inoculated into 96-well plates, and sample groups, blank control groups, positive control groups, and negative control groups were set up. At least 3 replicates were performed for each sample for each test indicator. After 24 hours of culture, the culture medium was discarded, and the corresponding CA sample solution was added to the sample group, the corresponding VC solution was added to the positive control group, and complete culture medium was added to the negative control group and the blank control group. After incubation in the incubator for 2 hours, hydrogen peroxide solution (0.8mMHX0640 Sigma-Aldrich) was added to the sample group, positive control group, and negative control group for inflammatory stimulation. The culture was continued for 24 hours.

[0120] Gene detection: discard the old solution, wash twice with PBS, add cell lysis solution to each well, blow and lyse the cells, and collect the samples. Extract RNA, reverse transcribe to cDNA, perform fluorescence quantitative PCR detection, and calculate the results using the 2-ΔΔCT method. The expression difference of the target gene in the two groups of samples is obtained by calculating the 2-ΔΔCt value.

[0121] (6) Transdermal test

[0122] Ex vivo skin preparation

[0123] The ex vivo skin stored at -20°C was thawed with deionized water at room temperature and repeatedly rinsed with PBS buffer.

[0124] Transdermal absorption capacity determination

[0125] 1) Fix the ex vivo skin between the donor chamber and the receiving chamber of the Franz cell diffusion tank, with the stratum corneum side of the skin facing the donor chamber and the dermis side facing the receiving chamber;

[0126] 2) Add receiving solution into the receiving chamber, tighten the skin and fix it, then add receiving solution (PBS) into the receiving chamber through the sampler, exhaust the air, and make the dermis of the skin in close contact with the receiving solution;

[0127] 3) Add sample: Add sample to the skin surface in the supply chamber. Spread the sample evenly from the center of the skin to the edge;

[0128] 4) Infiltration: Turn on the electromagnetic stirrer and stir at a speed of 300 rpm, and maintain a constant temperature water bath at (32±1)℃;

[0129] 5) Collect skin samples at 1 hour, 6 hours, and 18 hours, aspirate PBS to clean the skin surface, wipe off the residual liquid on the surface, and cut the skin with a blade. Frozen sections were set aside.

[0130] Observation and analysis

[0131] Skin sections were observed under a fluorescence microscope, photographed, and the fluorescence intensity was analyzed using Image J.

[0132] (7) In vitro anti-wrinkle test

[0133] 1) Cell seeding: 2.2×10 5 Fibroblasts were seeded into 6-well plates at a seeding density of 100 cells / well and incubated overnight in an incubator (37° C., 5% CO 2 ).

[0134] 2) Administration: The test groups were divided according to Table 2. When the cell plating rate in the 6-well plate reached 40-60%, the group administration was carried out, 2 mL of sample was added to each well, and 3 replicates were set for each group. After the administration, the 6-well plate was placed in an incubator (37° C., 5% CO2) and cultured for 24 hours.

[0135] 3) UVA irradiation: According to the experimental grouping, the group that needs UVA irradiation is irradiated with 30 J / c of ​​UVA and placed in an incubator (37° C., 5% CO 2 ) for a further 24 hours.

[0136] 4) Sample collection: After 24 hours of culture, collect the cell culture supernatant into an EP tube and store it in a -80°C refrigerator.

[0137] 5) ELISA test: The test was performed according to the operating instructions of the ELISA kit (Huamei Biotechnology CSB-E08082h).

[0138] (8) Anti-wrinkle and collagen-promoting under light conditions

[0139] Cell culture: HDF cells were cultured in DMEM complete medium (DMEM+10% FBS+1% P / S) and placed in a 37°C, 5% CO2 incubator.

[0140] Sample processing: CA powder was dissolved in the culture medium and after complete dissolution, the solution was sterilized by filtering with a 0.2 μm sterile filter membrane.

[0141] Experimental treatment: HDF cells were inoculated into 96-well plates, and sample groups, blank controls, and positive controls were set up. At least 3 replicates were performed for each sample for each test indicator. After 24 hours of culture, the culture medium was discarded, and the corresponding CA solution was added to the sample group, TGF-β solution was added to the positive control group, and complete culture medium was added to the negative control group and the blank group. The sample group, positive control group, and negative control group were placed under UVA light for 4 minutes at a power of 40 mW. After irradiation, the culture was continued for 24 hours.

[0142] Type I and III collagen detection: Collect the supernatant from each well and perform the test according to the operating instructions of the ELISA collagen detection kit (Huamei Biotechnology, CSB-E04799h).

[0143] (9) Cell viability-CCK8 detection

[0144] Seed plate: After thawing, HaCaT keratinocytes were cultured for 1-2 days until the cell confluence reached 70%. After trypsin digestion, keratinocytes were plated at 5×10 4 / well seed plates, grouped into DMEM, H2O2-DMEM, and H2O2-CA.

[0145] H2O2 stimulation: H2O2 (Shanghai Lingfeng Chemical Reagent) was used at a concentration of 0.8mM. It was first diluted to 10mM and then added to the culture medium at 100× (the original storage concentration was 8820mM, 10μL H2O2 was added to 8.82mL PBS, and 40μL of the dilution was added to 4mL culture medium). The prepared H2O2-containing culture medium was added to the H2O2 stimulation group in the form of liquid replacement and cultured for 2h.

[0146] CA treatment: 50 mg of UV-sterilized CA powder was added to 5 mL of PBS in advance, and the mixture was vortexed to dissolve into a 10 mg / mL liquid, which was then diluted with DMEM medium at a working concentration of 5 mg / mL. The culture supernatant after H2O2 stimulation was taken out (including the DMEM blank control group), and 100 μL of PBS was added to rinse each sample. Then, 100 μL of CA-containing culture medium was added to the H2O2-CA group, and 100 μL of culture medium was added to the DMEM and H2O2-DMEM groups, and cultured for 24 h.

[0147] CCK8 detection: Calculate the volume of culture medium required for the test, and then add CCK8 (Biyuntian, C0038) at 10×, that is, add 400μL CCK8 to 4mL culture medium). After aspirating the supernatant of each sample culture medium, add 100μL / well to a 96-well plate and incubate for 1-2h. Detect at OD450 using an ELISA reader in the dark. Example

[0148] The following examples are illustrative only and are not intended to limit the scope or content of the present invention in any way.

[0149] In the following examples, unless otherwise specified, the colanic acid used is sodium colanate having a molecular weight of 1-3 kDa.

[0150] Example 1

[0151] Cell culture: Human dermal fibroblast (HDF) cells were cultured in DMEM complete medium (DMEM+10% FBS+1% P / S) and cultured in a 37°C, 5% CO2 incubator.

[0152] Sample processing: CA powder was dissolved in the culture medium and after complete dissolution, the solution was sterilized by filtering with a 0.2 μm sterile filter membrane.

[0153] Experimental treatment: HDF cells were inoculated into 96-well plates, and sample groups, blank controls, positive controls, and negative controls were set up. At least 3 replicates were performed for each sample for each test indicator. After 24 hours of culture, the culture medium was discarded, the corresponding CA solution was added to the sample group, the VC solution (dissolved in the culture medium) was added to the positive group, and complete culture medium was added to the negative control group and the blank group. Place in an incubator and incubate for 24 hours. The cells were then taken out and frozen, and GeneWeichi was commissioned to conduct transcriptome analysis.

[0154] Figure 3 It shows that oligomeric CA (Oli-CA) promotes AMPK, PGC1α and Cab39 ( Figure 3 A), and NAMPT, sirtuin1, sirtuin6, and sirtuin7 ( Figure 3 B) transcription of genes. Figure 3 The results showed that oligomeric colanic acid promoted the expression of sirtuin1 in human fibroblasts.

[0155] Example 2

[0156] Oligomeric colanic acid (2.5 mg / mL), HA (hyaluronic acid, 2.5 mg / mL), Ectoin (2.5 mg / mL), NC (UV light only), PC (Cucurbitacin 1 mg / mL), and BC (cells only) were added to fibroblasts and cultured for 24 hours. Then, the cell survival rate was observed by UV light irradiation, and the transcriptional effect of oligomeric CA on BAX and NF-κB inhibitory protein in human fibroblasts was tested. The results are shown in Figure 2. Figure 4 shown. Figure 4 The results showed that oligomeric CA inhibited BAX transcription and upregulated NF-κB inhibitory protein transcription ( Figure 4A); After adding oligomeric CA, HA, Ectoin and vitamin C (positive control), the cells were tested for cell viability after illumination. The above experimental results show that oligomeric colanic acid can significantly improve the survival rate of cells under ultraviolet conditions and has a good effect in inhibiting cell apoptosis.

[0157] Example 3

[0158] According to the method of inflammation (macrophages) in the experimental method, the inhibitory effect of oligomeric CA on mouse macrophage inflammation was tested. The results are as follows Figure 5 As shown. Figure 5 It can be learned that oligomeric colanic acid can effectively inhibit the inflammatory response of macrophages induced by LPS (lipopolysaccharide), including TNF-α ( Figure 5 A) and IL-6 ( Figure 5 B) etc.

[0159] Example 4

[0160] According to the experimental method of Example 1, the transcriptional regulation effect of oligomeric CA on genes related to mitochondrial homeostasis repair in human fibroblasts was tested. The results are as follows: Figure 6 shown. Figure 6 It was shown that oligomeric colanic acid can upregulate the transcription of a series of genes, including AMBRA1, USP8, ATF4, BNIP3 and BCL2L13, ATF5 and CHOP.

[0161] Example 5

[0162] The oligomeric CA was tested for its effect on the transcriptional analysis of SOD2 and GPX1 / 8 in human fibroblasts and the scavenging effect on reactive oxygen species (Solebo, ROS detection kit). The results are as follows Figure 7 As shown. Figure 7 It can be observed that oligomeric CA can largely upregulate the transcriptional levels of SOD2, GPX1 and GPX8 in human fibroblasts ( Figure 7 A), and at the same time, the reactive oxygen species produced by human fibroblasts irradiated by UV were significantly inhibited ( Figure 7 B). This indicates that oligomeric colanic acid has a good activity in regulating the scavenging of reactive oxygen species in cells.

[0163] Example 6

[0164] According to the anti-wrinkle (pro-collagen) experimental method in the experimental method, the oligomeric CA was tested to promote the synthesis of type I collagen in HDF cells and upregulate the transcription of different types of collagen in HDF cells. The results are as follows Figure 8 shown. Figure 8 It shows that oligomeric CA can significantly increase the amount of type I collagen synthesized by HDF cells (the data in the figure were measured by diluting the supernatant 10 times with culture medium). Figure 8It can be seen from A that oligomeric CA has a higher collagen regeneration activity than Pro-Xylane and retinol propionate (RP) under the same concentration conditions. At the same concentration, its collagen regeneration activity is 4 times that of Pro-Xylane (2 mg / mL) and 3-4 times that of retinol propionate (3 mg / mL, 10 mg / mL). In addition, the transcriptome analysis results of HDF cells ( Figure 8 B) It can also be observed that oligomeric CA has a transcriptional upregulation effect on many other types of collagen, including type 4, type 6, type 7, type 9, type 17, type 22, type 25, etc. This result shows that oligomeric CA has a good application prospect in promoting collagen activity.

[0165] Example 7

[0166] According to the experimental method of light damage in the experimental method, the phototoxicity of oligomeric colanic acid was tested, and the results were as follows Fig. 9 shown. Fig. 9 It shows that when HDF cells were exposed to light after adding oligomeric colanic acid CA, no obvious cytotoxicity was observed (cell activity > 90% can be considered non-toxic). On the contrary, as the amount of oligomeric colanic acid added increased, the protective effect on cells increased from 90% at 2 mg / mL to 97% at 10 mg / mL. Retinyl propionate showed significant cytotoxicity under the conditions of 3 mg / mL and 10 mg / mL.

[0167] Example 8

[0168] According to the method of anti-wrinkle and collagen-promoting under light conditions in the experimental method, the activity of oligomeric colanic acid in promoting the synthesis of type I collagen and type III collagen by HDF cells under light conditions was tested. The results are as follows Fig.10 shown.

[0169] Fig.10 It was shown that oligomeric colanic acid showed stronger activity in promoting type I and type III collagen in the light-irradiated HDF cell model. Compared with phosphene, at a concentration of 2 mg / mL, oligomeric colanic acid promoted type I collagen 2.3 times and type III collagen 2.8 times. Compared with retinol propionate, under the same concentration conditions, it promoted type I collagen 18 times (3 mg / mL) and 2 times (10 mg / mL), and promoted type III collagen 10 times (3 mg / mL) and 28 times (10 mg / mL). It can be seen that oligomeric colanic acid not only has no phototoxicity, but also has the activity of promoting type I and type III proteins at the same time, and its efficacy is significantly higher than that of phosphene and retinol propionate.

[0170] Example 9

[0171] The inhibitory effect of oligomeric colanic acid on MMP9 in the UV-irradiated skin model was tested (Huamei Biotechnology, CSB-PA002676), and the proteomic data of the skin under UV-irradiation in vitro were obtained. Fig.11 It can be observed that the content of MMP9 in the group with added colanic acid decreased significantly. MMP9 is a key target for inhibiting DEJ aging. Increased MMP9 skin content will lead to a rapid loss of type VI collagen in the DEJ layer, which in turn causes the DEJ to become smooth. The DEJ layer is the connecting layer between the dermis and the epidermis. The smoother it is, the less connection there will be between the dermis and the epidermis, and skin aging will be aggravated.

[0172] Example 10

[0173] According to the cell culture and modeling methods in the experimental method of inflammation (keratinocytes), TNF-α, IL-6 and COX-2 were detected (ELSIA kit: Huamei Bio, CSB-E04740h, CSB-E04638h, CSB-E10103h) to test the anti-inflammatory effect of oligomeric colanic acid on human keratinocytes. Fig.12 It was shown that oligomeric colanic acid had a good anti-inflammatory effect on human keratinocytes and could significantly inhibit the expression of TNF-α, IL-6 and COX-2 at 1 mg / mL.

[0174] Embodiment 11

[0175] The skin permeability of oligocoranic acid was tested according to the transdermal test method in the experimental method. Fig.13 After oligomeric colanic acid was fluorescently labeled, the skin permeability test of the ex vivo skin showed that the amount of the molecule permeated significantly increased within 18 hours, and the fluorescence intensity increased by 9 times. At the same time, it was observed that the molecule could effectively penetrate into the dermis.

[0176] The intracellular localization of oligomeric colanic acid was tested by the following method.

[0177] Cell culture: HDF cells were cultured in DMEM complete medium (DMEM+10% FBS+1% P / S) and placed in a 37°C, 5% CO2 incubator.

[0178] Sample treatment: 1 mg / mL fluorescently labeled CA powder was dissolved in the culture medium and filtered through a 0.2 μm sterile filter membrane after complete dissolution.

[0179] Experimental treatment: HDF cells were inoculated into 96-well plates, and sample groups, blank controls, and positive controls were set up. At least 3 replicates were performed for each sample for each test indicator. After 24-48 hours of culture, the cells were removed, and DAPI and Mitotracker staining solutions were added to stain the cell nucleus and mitochondria, respectively. After each staining, the cells were washed with PBS two to three times, and finally the fluorescence was observed under an optical microscope.

[0180] Fig.14 This shows that oligomeric colanic acid can effectively enter the cell, and through the mitochondrial staining of mitotracker, it can be observed that oligomeric colanic acid (green) and mitochondria (red) overlap, which shows that oligomeric colanic acid can pass through the cell membrane and enter the mitochondria. In contrast, there is no overlap between colanic acid and the cell nucleus (blue), so we believe that oligomeric colanic acid is more difficult to enter the cell nucleus.

[0181] In addition, the cytotoxicity test results of oligomeric colanic acid ( Fig.15 ) showed that the molecule had no cytotoxicity below a concentration of 10 mg / mL.

[0182] Example 12: Human Experimental Test

[0183] The human body experiment of oligomeric sodium colanate was carried out according to the following method. The results are as follows Figure 16-25 shown.

[0184] 66 healthy Chinese male / female subjects with dry, loose, and inelastic faces, skin elasticity R2 between 0.35 and 0.55, fine lines or wrinkles on the face, wrinkles at the corners of the eyes at levels 2 to 5, weak skin barriers, and sensitive skin were randomly divided into two groups, 33 in each group, with an age range of 30 to 60 years old. The subjects' stratum corneum moisture content, transepidermal water loss, skin elasticity, skin firmness, dermal density, dermal thickness, and total skin thickness were measured by the method of before-after control and between-group control for subjective evaluation and local and full-face photos were taken. The test results were compared by statistical test methods to determine whether there were statistical differences.

[0185] Detection area

[0186] (1) Water content of the stratum corneum of the skin - cheeks

[0187] (2) Transepidermal water loss value - cheek

[0188] (3) Skin elasticity R2 - cheek

[0189] (4) Skin firmness F4 - Cheeks

[0190] (5) UC22 Dermal Density - Cheek

[0191] (6)UC22 Dermis Thickness - Cheek

[0192] (7) UC22 full skin thickness - cheek

[0193] (8) PRIMOS CR Wrinkle area under the eyes - under the eyes

[0194] (9) PRIMOS CR Under-eye wrinkle volume - Under-eye

[0195] (10) PRIMOS CR cheek roughness Ra - cheek

[0196] (11)VISIA CR skin color L value - full face photo analysis of cheeks

[0197] (12)VISIA CR skin color b value - full face photo analysis of cheeks

[0198] (13)VISIA CR skin color ITA° value - full face photo analysis of cheeks

[0199] (14)VISIA CR skin transparency parameters - whole face

[0200] (15)VISIA CR skin gloss parameter - full face photo analysis of cheeks

[0201] (16)VISIA CR skin red area ratio - full face photo analysis cheek

[0202] (17)VISIA CR eye corner wrinkle area ratio - full face photo analysis of eye corners

[0203] (18)VISIA CR Pore Area Ratio - Full Face Photo Analysis Cheeks

[0204] (19)VISIA CR jaw line angle - full face photography to analyze the jaw

[0205] (20) Standardized area of ​​the epidermal dermal junction DEJ layer DEJI - corner of the eye

[0206] (21) Aging Index ELCOR - Canthus

[0207] (22) Aging Index SAAID - Canthus

[0208] (23) Epidermal thickness TED - corner of eye

[0209] (24) Elastic fiber fluorescence intensity - corner of eye

[0210] (25) Collagen fiber harmonic intensity - corner of eye

[0211] (26) Assessment of eye wrinkle levels - eye corners

[0212] (27) Assessment of wrinkles under the eyes - Under the eyes

[0213] (28) Glossiness score - cheeks

[0214] (29) Elasticity score - cheek

[0215] (30) Smoothness score - cheeks

[0216] (31) Smoothness score - cheeks

[0217] (32) Self-assessment - Full face

[0218] Day 0:

[0219] When the subjects come for a visit, technicians will assess the facial skin condition of the subjects and select those with dry skin or wrinkles and redness from the subjects participating in the trial;

[0220] Clean the face and wait: The subjects cleaned their faces with a facial cleanser, dried their skin with dry facial tissue, and sat quietly in a laboratory at a temperature of 21°C ± 1°C and a humidity of 50% RH ± 10% RH for 20 minutes;

[0221] Data collection of skin basal values ​​of test subjects: Laboratory technicians used SUPERVISION 780, VISIACR, Cutometer, PRIMOSCR, Corneometer, Vapometer, and UC22 instruments to measure the basal values ​​of relevant indicators on the test sites of the subjects;

[0222] Trained dermatologists professionally rated and recorded the subjects' eye wrinkles;

[0223] Professional assessors will score and record the subjects' skin gloss, fineness, smoothness, and elasticity;

[0224] The laboratory technicians instructed the subjects to use the product according to the product usage requirements and provided written test precautions and product instructions. According to the random table, the subjects were randomly divided into two groups, and one person in each group was randomly selected to use the product on half of the face. The moisture test was performed on multiple points on the face 2h and 4h after using the product.

[0225] The subjects received the products and left the laboratory.

[0226] Day 14:

[0227] Subjects return visit, clean face and wait: clean face with cleansing products, dry skin with dry facial tissue, sit in a laboratory with temperature 21℃±1℃, humidity 50%RH±10%RH for 20 minutes, and complete the D14 self-assessment questionnaire during the 20 minutes of sitting;

[0228] D14 data collection of test subjects' skin: laboratory technicians operated SUPERVISION 780, VISIA CR, Cutometer, PRIMOSCR, Corneometer, Vapometer, and UC22 instruments to measure relevant indicators on the test sites of the subjects;

[0229] Trained dermatologists professionally rated and recorded the subjects' eye wrinkles;

[0230] Professional assessors will score and record the subjects' skin gloss, fineness, smoothness, and elasticity;

[0231] Staff checked subjects’ usage records and products;

[0232] The subject leaves the laboratory.

[0233] Day 28:

[0234] Subjects return visit, clean face and wait: clean the face with cleansing products, dry the skin with dry facial tissues, sit in a laboratory with a temperature of 21℃±1℃ and a humidity of 50%RH±10%RH for 20 minutes, and complete the D28 self-assessment questionnaire during the 20 minutes of sitting;

[0235] D28 data collection of test subjects' skin: laboratory technicians operated SUPERVISION 780, VISIA CR, Cutometer, PRIMOSCR, Corneometer, Vapometer, and UC22 instruments to measure relevant indicators on the test sites of the subjects;

[0236] Trained dermatologists professionally rated and recorded the subjects' eye wrinkles;

[0237] Professional assessors will score and record the subjects' skin gloss, fineness, smoothness, and elasticity;

[0238] Staff checked and collected the subjects' usage records and products;

[0239] The subject left the laboratory;

[0240] The testing process is finished.

[0241] Fig.16The results show that oligomeric sodium colanate has an effect on increasing the density of the human dermis. Fig.16 It can be seen that when the subjects used the serum containing 0.5% (w / v) sodium oligocorticate for 14 consecutive days, the UC22 dermal density increased by 22.87%; after continuous use for 28 days, it increased by 24.00%.

[0242] Fig.17 The results show that oligomeric sodium colanate has an effect on increasing the expression of collagen in the human dermis. Fig.17 It can be seen that when the subjects used the serum containing 0.5% (w / v) sodium oligocorticate for 14 consecutive days, the harmonic intensity of collagen fibers increased by 12.31%, and when used for 28 consecutive days, it increased by 21.61%.

[0243] Fig.18 The results show that oligomeric sodium colanate has an effect on increasing the expression of elastin in the human dermis. Fig.18 It can be seen that when the subjects used the serum containing 0.5% (w / v) sodium oligocorticate for 14 consecutive days, the fluorescence intensity of elastic fibers increased by 17.02%, and when used for 28 consecutive days, it increased by 22.13%.

[0244] Fig.19 The results show that oligomeric sodium colanate has an effect on improving the elasticity and refinement of human skin. Fig.19 It can be seen that when the subjects used the essence containing 0.5% (w / v) sodium oligocorticate for 14 consecutive days, the skin elasticity R2 increased by 24.44% and the skin firmness F4 decreased by 6.62%; after continuous use for 28 days, R2 increased by 40.00% and F4 decreased by 12.00%.

[0245] Fig. 20 The results show the effect of oligomeric sodium colanate on the normalized area of ​​DEJ in human skin. Fig. 20 It can be seen that when the subjects used the essence containing 0.5% (w / v) sodium oligocorticate for 14 consecutive days, the standardized area DEJI of the epidermal dermal junction layer increased by 28.70%; after 28 consecutive days, it increased by 36.11%.

[0246] Fig.21 The results show the effect of oligomeric sodium colanate on the thickness of the epidermis of human skin. Fig.21 It can be seen that when the subjects used the serum containing 0.5% (w / v) sodium oligocorticate for 14 consecutive days, the increase rate of epidermal thickness was 27.78%, and when used for 28 days, the increase rate was 27.29%.

[0247] Fig. 22 The results show that oligomeric sodium colanate has an effect on improving the redness of human skin. Fig. 22It can be seen that when the subjects used the serum containing 0.5% (w / v) oligocorticosteroids for 28 consecutive days, the proportion of VISIA-CR skin red area decreased by 10.45%.

[0248] Fig.23 The results show the effect of oligomeric sodium colanate on the content of 3D skin filaggrin (FLG). Fig.23 The results of the 3D skin experiment test showed that compared with the BC control group, the content of filaggrin (FLG) in the oligomeric sodium colanate at a concentration of 0.5% (w / v) was significantly increased, with an increase rate of 49.00%.

[0249] Fig.24 The results show that oligomeric sodium colanate has an effect on increasing the content of 3D skin aquaporin 3 (AQP3). Fig.24 The results of the 3D skin experiment test showed that compared with the BC control group, the content of aquaporin 3 (AQP3) in the oligomeric sodium colanate at a concentration of 0.5% (w / v) was significantly increased, with an increase rate of 37.00%.

[0250] Fig.25 The results show the effect of oligomeric sodium colanate on the moisture retention of human skin. Fig.25 It can be seen that after the subjects used the serum containing 0.5% (w / v) sodium oligocorticate for 14 days, the water content of the stratum corneum increased significantly by 31.76%; after 28 days of use, it increased by 63.84%. The transepidermal water loss value of the skin decreased significantly by 12.57% compared with the baseline value; after 28 days of use, it decreased by 20.08%.

[0251] Example 13

[0252] Sodium colanate with a molecular weight of 1-10 kDa, 1-8 kDa, 1-6 kDa, 1-5 kDa, 1-4 kDa, 1-2 kDa, 2-10 kDa, 2-8 kDa, 2-6 kDa, 2-4 kDa, 2-3 kDa, 3-6 kDa, 4-10 kDa, 4-8 kDa, 4-6 kDa, 5-10 kDa, 5-8 kDa, 6-10 kDa, or 6-8 kDa was prepared in the same manner as in Examples 1-12, and its properties and efficacy were tested.

[0253] Embodiment 14

[0254] According to the anti-wrinkle (collagen-promoting) method in the experimental method, the effect of sodium colanate (CA) with different molecular weights at a concentration of 3 mg / mL on stimulating human fibroblasts to express type I collagen was tested. The results are as follows: Fig.26 As shown. Fig.26It can be seen that oligomeric sodium colanate with molecular weights in the range of 1-3 kDa and 3-10 kDa has better anti-aging and collagen-promoting activity.

[0255] According to the cell viability-CCK8 method in the experimental method, the skin protection effect of sodium colanate (CA) with different molecular weights was tested. The results are as follows Fig. 27 As shown. Fig. 27 It can be seen that oligomeric sodium colanate with molecular weights in the range of 1-3 kDa and 3-10 kDa has better skin protection effect.

[0256] Incorporated by Reference

[0257] Each patent and scientific article mentioned herein is incorporated by reference in its entirety for all purposes.

[0258] Equivalence

[0259] The present invention may be embodied in other specific ways without departing from its spirit or essential characteristics. Therefore, the above embodiments should be regarded as illustrative in all cases, rather than limiting the invention described herein. Therefore, the scope of the present invention is indicated by the appended claims rather than by the above description, and it is intended that all changes within the equivalent meaning and scope of the claims are included therein.

Claims

1. Use of colanic acid or a physiologically acceptable salt thereof, or a composition comprising colanic acid or a physiologically acceptable salt thereof, in skin anti-aging and / or skin protection, characterized in that: The molecular weight of the colanic acid or its physiologically acceptable salt is in the range of 1-10 kDa, preferably in the range of 1-3 kDa or 3-10 kDa.

2. The use according to claim 1, wherein The skin anti-aging method includes increasing the collagen content in the skin, preferably increasing the content of type I and type III collagen.

3. The use according to claim 1, wherein The skin protection includes enhancing the protective function of skin cells such as improving the vitality of skin cells.

4. The use according to claim 1, wherein The skin anti-aging and the skin protection include improving the skin condition or appearance.

5. The use according to any one of claims 1 to 4, wherein The content of colanic acid or its physiologically acceptable salt is 0.01-10% (w / v), preferably 0.1-5% (w / v), more preferably 0.5-3% (w / v).

6. The use according to any one of claims 1 to 5, wherein The physiologically acceptable salt of colanic acid is sodium colanate.

7. The composition according to any one of claims 1 to 6, wherein The colanic acid or a physiologically acceptable salt thereof, or a composition comprising colanic acid or a physiologically acceptable salt thereof, is formulated for topical, oral, intramuscular, subcutaneous or intravenous administration.

8. The composition according to any one of claims 1 to 7, wherein The composition comprising colanic acid or a physiologically acceptable salt thereof further contains cosmetically or pharmaceutically acceptable additives.

9. A composition, characterized in that The composition comprises colanic acid or a physiologically acceptable salt thereof as an effective ingredient, wherein the molecular weight of the colanic acid or a physiologically acceptable salt thereof is in the range of 1-10 kDa, preferably in the range of 1-3 kDa or 3-10 kDa.

10. The composition according to claim 9, wherein The content of colanic acid or its physiologically acceptable salt in the composition is 0.01-10% (w / v), preferably 0.1-5% (w / v), more preferably 0.5-3% (w / v).

11. The composition according to claim 9 or 10, wherein The composition contains only colanic acid or its physiologically acceptable salt as an active ingredient.

12. The composition according to any one of claims 9 to 11, wherein The compositions are formulated for topical, oral, intramuscular, subcutaneous or intravenous administration.

13. A composition according to any one of claims 9 to 12, wherein The composition may also contain cosmetically or pharmaceutically acceptable additives.

14. A composition according to any one of claims 9 to 13, wherein The physiologically acceptable salt of colanic acid is sodium colanate.

Citation Information

Patent Citations

  • Scalable method for purifying corac acid

    CN114957509A

  • Collamyric acid fermentation scale-up process

    CN115287314B

  • High-efficiency expression of kola tarase-degrading enzyme and its application in the preparation of kola tarase oligosaccharides with specific molecular weights

    CN116334039B

Cited By

  • Use of composition comprising colanate

    WO2026001394A1

  • Use of colanic acid-containing composition in skin Anti-aging

    WO2026067814A1